Compare Fubotv Inc (FUBO) vs Hims and Hers Health Inc (HIMS) Price & Performance

FUBO trades at $9.54, down 2.95% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $172.25 million in 2024, but revenue grew to $1.62 billion, and profitability improved significantly in 2025 with a net income margin of 7.61%. Valuation ratios appear low, with a P/E of 2.67 and P/S of 0.21. Recent news highlights the appointment of a new CEO from Disney, sparking investor optimism about future growth.

The outlook is mixed; low valuations and a path to profitability present opportunity, but persistent cash flow challenges and high debt levels pose significant risks. Analyst consensus is a Buy with a $16.25 price target, suggesting substantial upside if the new leadership can execute on growth and monetization strategies effectively.

Hims & Hers Health trades at $35.52, up 1.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $33.57. Recent earnings show volatility with a Q1 2026 miss, but revenue grew to $2.35 billion in 2025. The company benefits from expansion in weight-loss therapies and a $400 million JPMorgan facility, though high valuations like a P/E of 57.14 and negative net income margin pose concerns.

Outlook is mixed: growth opportunities in telehealth and GLP-1 drugs support upside, but earnings inconsistency and regulatory risks from FDA reviews require caution. Analysts are 35% buy-rated, highlighting potential if execution improves, yet investors face volatility near key resistance at $38.